Defense against intestinal infection in organism is affected by prostaglandin E2

November 15, 2018 by André Julião, FAPESP
Defense against intestinal infection in organism is affected by prostaglandin E2
Experimental inhibition of this prostanoid led to increased migration of defense cells and production of antimicrobial peptides, resulting in decreased bacterial numbers in the colon. Credit: comparison between microscopic images of distal colonic tissue from C. rodentium-infected mice and indomethacine-treated mice/ PNAS

The treatment of intestinal infections caused by some strains of the bacterium Escherichia coli, present in unsanitized or contaminated foods, may have a new ally.

A study published in PNAS reports that the inhibition of prostaglandin E2 (PGE2), a lipid mediator released during the process of infected cell clearance (efferocytosis) in the intestine, enhanced the ability of mice to combat infectious colitis.

"Tissue cell death is intense during a bacterial infection. Many immune cells recruited to the site of the infection also die. We found that during the removal of dead and infected cells, a process called efferocytosis, there was an increase in the release of proteins and of the lipid mediator prostaglandin E2. However, the presence of PGE2 impaired the differentiation of Th17 [or T helper 17] cells, lymphocytes that play a key role in the resolution of ," said Alexandra Ivo de Medeiros, a professor at São Paulo State University's School of Pharmaceutical Sciences (FCF-UNESP) in Araraquara, Brazil, and principal investigator for the study.

To prove this hypothesis, the researchers inhibited the production of PGE2 using such as indomethacin and ibuprofen. The inhibition of PGE2 resulted in increased differentiation of Th17 cells.

"Th17 cells play a key role in resolving bacterial intestinal infection by promoting the recruitment of inflammatory cells and the production of ," Medeiros told.

The study funded by São Paulo Research Foundation -FAPESP also showed that blocking only one PGE2 receptor, EP4, reversed the suppressive effect of PGE2 on the differentiation of Th17 cells.

Different functions

"Prostaglandin E2 can perform different functions depending on the type of cell and receptor involved. Our use of the EP4 prostaglandin receptor antagonist enhanced the resolution of infectious colitis," said Naiara Naiana Dejani, first author of the article. Dejani earned her Ph.D. with a scholarship from FAPESP.

Another finding of the study was that inhibiting prostaglandin synthesis or signaling by treatment with the EP4 antagonist L-161,982 favored the expression of defensins, which are considered natural antibiotics, in the colon.

"The use of a specific antagonist of the PGE2 receptor, such as the EP4 receptor antagonist, offers advantages in terms of an auxiliary proposal for the treatment of infectious colitis. Nonselective nonsteroidal anti-inflammatory drugs, or NSAIDs, such as indomethacin and ibuprofen, are inexpensive but can cause adverse events that have been well described in the literature," Dejani said.

Despite the protective effect of Th17 cells in bacterial infection, these same cells may cause chronic inflammation and autoimmune disease, so while the discovery points to an important potential ally of antibiotics in treating infections, a buildup of Th17 in the intestine could result in future complications.

Infection

In the experiment, mice were orally infected with a bacterium (Citrobacter rodentium) that mimics by E. coli in humans. After 24 hours, they began receiving a one-week treatment. Indomethacin was administered every two days to one group, while a second group received a daily dose of L-161,982 (the EP4 antagonist). Controls were given an innocuous substance.

Analysis of the intestine in all groups at the end of the treatment showed that the use of an EP4 antagonist may be a promising strategy for the auxiliary treatment of infectious colitis. However, further research is required to show whether combining the EP4 antagonist and antibiotic therapy improves the resolution of this .

Explore further: Combination therapy boosts antiviral response to chronic infection

More information: Naiara Naiana Dejani et al, Intestinal host defense outcome is dictated by PGE2 production during efferocytosis of infected cells, Proceedings of the National Academy of Sciences (2018). DOI: 10.1073/pnas.1722016115

Related Stories

Combination therapy boosts antiviral response to chronic infection

March 23, 2015
A Yale-led team has identified a promising new combination immunotherapy to enhance the body's ability to fight chronic viral infections and possibly cancer.

Researchers report mechanisms governing body temperature regulation

August 31, 2018
Researchers from Kanazawa University report in the Journal of Neuroscience on a microdialysis study on mice to determine mechanisms underlying the inflammatory response in the brain associated with fever. Their findings might ...

Researchers identify immune culprits linked to inflammation and bone loss in gum disease

October 17, 2018
An unhealthy population of microbes in the mouth triggers specialized immune cells that inflame and destroy tissues, leading to the type of bone loss associated with a severe form of gum disease, according to a new study ...

Researchers find that influenza has an Achilles' heel

April 10, 2014
Flu epidemics cause up to half a million deaths worldwide each year, and emerging strains continually threaten to spread to humans and cause even deadlier pandemics. A study published by Cell Press on April 10 in the journal ...

Inflammatory molecule essential to muscle regeneration in mice, researchers find

June 12, 2017
A molecule released as part of an inflammatory response after muscle injury or rigorous exercise activates muscle stem cells responsible for repairing the damage, according to a study by researchers at the Stanford University ...

Unraveling the immunopathogenesis of Johne's disease

April 2, 2018
Researchers of Hokkaido University, the National Agriculture and Food Research Organization (NARO), and Tohoku University demonstrated that a physiologically active substance called prostaglandin E2 (PGE2) impairs the immune ...

Recommended for you

Newly identified T cells could play a role in cancer and other diseases

December 6, 2018
Researchers from the UCLA Jonsson Comprehensive Cancer Center and the La Jolla Institute for Immunology have identified a new type of T cell called a phospholipid-reactive T cell that is able to recognize phospholipids, the ...

Classifying brain microglia: Which are good and which are bad?

December 6, 2018
Microglia are known to be important to brain function. The immune cells have been found to protect the brain from injury and infection and are critical during brain development, helping circuits wire properly. They also seem ...

Memory B cells in the lung may be important for more effective influenza vaccinations

December 5, 2018
Seasonal influenza vaccines are typically less than 50 percent effective, according to Centers for Disease Control and Prevention studies. Research at the University of Alabama at Birmingham, published this week in Nature ...

Tuberculosis survives by using host system against itself, study finds

December 5, 2018
In a new study published in the Journal of Experimental Medicine, scientists at the University of Notre Dame have discovered that the pathogen Mycobacterium tuberculosis (MTB) releases RNA into infected cells. This RNA stimulates ...

RSV study reveals age when infants are most vulnerable to asthma

December 5, 2018
New research suggests a maternal vaccination against RSV should be augmented with active immunisation in a child's first two years to reduce the onset of asthma.

New Zika vaccine effective in preclinical trials

December 4, 2018
Researchers at the University of Hawaii medical school have successfully developed a vaccine candidate for the Zika virus, showing that it is effective in protecting both mice and monkeys from the infection.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.